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1. Introduction
Hair loss (alopecia) is a prevalent dermatological course and it has an impact on both females 
and males of all ages. For centuries, hair has been the most important sign for the females. 
Healthy hair is an essential factor for physical well‐being and females can show their charm, 
beauty and personal power with healthy hair. That is why hair loss can cause psychological 
problems for women rather than for men.
The term alopecia comes from the Greek alopex, ‘fox’, originally referring to mange in foxes, 
and can be associated with a wide variety of conditions such as genetic, autoimmune, infec‐
tious and environmental. Many people face this dermatological condition. The appearance of 
hair loss can diversify according to what causes this disease. The whole body and scalp can be 
affected abruptly and gradually. Temporary and permanent hair loss can occur. Sometimes, it 
is not necessary to apply any treatment to grow hair again, but sometimes, it is an obligation 
to treat hair loss. Sometimes, hair will not re‐grow.
Hair is one of the characteristic features of mammals. Hair is an essential speciality for pro‐
tecting humans from environmental factors, producing sebum and pheromones and apocrine 
sweat. It affects someone's role in sexual and social relationships. Hair acts a major role for 
thermoregulation and it is a resource for stem cells [1].
Hair is a derivate of the epidermis. Hair has two different parts: one of them is the hair shaft 
and the other is the follicle. The generation of hair depends on the follicle. Cortex, cuticle cells 
and a medulla for some types of hairs are the parts of the hair shaft. Hair follicle is an essential 
part for hair growth and it grows continuously. The continuous growth and rest sequence is 
named hair cycle. The span of hair growth depends on many endocrine, neural stimuli and 
vascular stimuli. Various factors such as age, localization of the hair and nutritional habits 
have an impact on the nature of hair.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Nearly there are 5 million hair follicles in humans, and scalp has 100,000 of them. Mainly 
terminal hairs are on scalp, eyelashes and eyebrows, whereas vellus hairs cover the rest of the 
body [2]. Hair is formed in two different parts: follicle is located under the skin and it is the 
living part and the other one is the hair shaft, above the skin surface, and it is fully keratinized 
non‐living part. Hair development is a continuous cyclic process. Hair growth cycle consists 
of growth (anagen), regression (catagen), rest (telogen) and shedding (exogen); mature fol‐
licles go through all of these process. The location of the hair, hormonal balance, personal 
nutrition and age can affect the duration of the phases [3, 4].
Especially feminine appearance, attractiveness, personal image and sexuality can be affected 
according to the healthy hair. Hair is an important point for a healthy look, social image and 
communication. All individuals complain about hair loss without thinking about age and 
gender but hair loss can have more dramatical effects on females than on males, because hair 
loss can change the life quality and social communication. That is why dermatological clinics 
take much interest in hair loss problems.
Hair loss can be due to a wide variety of causes such as scarring and non‐scarring diseases.
Alopecia areata (AA), which is an inflammatory disease, causes non‐scarring patchy hair loss 
of the scalp and whole body; it occurs depending on genetic and autoimmune basis [5]. The 
lifetime coincidence of this chronic disease is 2.1%. This inflammatory disease begins with 
circular hair loss with sudden sharp borders [6]. The etiology of this disease can be genetic, 
infectious, immunological, environmental or psychological even though the etiopathogenesis 
is not known. Some genes such as TRAF1/C5 locus can be a reason for genetic disposition [7]. 
Some autoimmune disorders, such as Hashimoto's thyroiditis or vitiligo, which are related to 
diseases of T‐cell, can accompany hair loss problems. Some studies point out that the risk of 
alopecia areata can be increased by the history of atopy [8]. In the pathogenesis of the disease, 
cytokines such as IFN‐gamma, interleukins and TNF‐alpha are important factors. The patients 
with normal appearing underlying skin are presented with asymptomatic and patchy hair 
loss. The beginning point of this disease is generally scalp hair, and then it can spread to eye‐
brows, eyelashes and total body. If a patient has a limited involvement, it can re‐grow sponta‐
neously. But some patients have a chronic and recurrent course, with many attacks over years.
Physicians think that the treatment of alopecia can be so challenging. Variable treatments 
with different effects can be applied to the patients. These treatments consist of systemic, 
intralesional or topical corticosteroids, systemic or local phototherapy, cyclosporine‐A, acu‐
puncture, interferon‐α, anthralin, topical immunotherapy agents, topical minoxidil and 
photodynamic therapy [9–11]. Although the stem cells of hair follicles spread into the scalp 
typically in order to re‐grow hair, there are no useful and existing treatments to recover alo‐
pecia areata. It is a chronic disease and the consequences can be disruptive for psychological 
and physical appearance. The impressiveness of treatments decreases due to the spontaneous 
relapses and remissions and these courses can be unpredictable. This application has been 
shown as allergic contact dermatitis; topical sensitizers have a major role to begin a delayed‐
type (type IV) hypersensitivity reaction by acting as haptens. To make a complete antigen, 
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these sensitizers help to bind to an endogenous protein. There are some applications to aim 
topical sensitization such as dinitrochlorobenzene, SADBE and DPCP [11].
The quality of life is also affected by AA; in most studies, AA is the sort of alopecia, and 
psychological and social factors have an impact on this disease. The incidence of lifetime 
major depressive symptoms and anxiety disorders in AA patients was estimated as 39% in 
one study [12]. Besides, antisocial personality disorder and post‐traumatic stress disorder 
were observed at a high rate in those patients. In AA patients, antisocial personality and post‐
traumatic disorders were found at a high rate.
Androgenetic alopecia occurs commonly in males and it is a male‐type hair loss. This dis‐
ease is known as the most common form of hair loss; it is progressed by alopecia areata, tinea 
capitis, telogen effluvium and scarring alopecia [13]. The most essential point of this course is 
genetic and hormonal reasons. It has been found that middle‐aged white men are generally 
exposed to this disease. This problem affects mostly 30% of white men at the age of 30, 50% 
at the age of 50 and 80% at the age of 70 [14]. Androgenetic alopecia begins with gradual thin 
hair in the temporal area and then it follows reshaping of the anterior part of the hairline. 
According to Norwood‐Hamilton classification, it ends with baldness. Androgenetic alope‐
cia is also observed in women, but the thinning of hair happens in different areas. In women, 
this disease does not commence on marked baldness; it is found especially on the crown. The 
progression is mostly seen according to the Ludwig scale [13]. Medications approved by the 
Food and Drug Administration (FDA) to treat male‐pattern hair loss include minoxidil and 
finasteride. By using these medications, hair loss may be reversed or slowed in early phases.
Scarring alopecias or cicatricial alopecias are a group of rare inflammatory hair loss diseases; 
hair follicles are devastating permanently in these diseases. The most common symptom of 
this disease is the loss of apparent follicular ostia in a scarring area. The most important his‐
topathological characterization of this disease is the replacement of the hair follicle structure 
made from fibrous tissue. Cicatricial alopecias have various types such as primary cicatricial 
alopecia, secondary cicatricial alopecia and hereditary cicatricial alopecia. The reason for pri‐
mary cicatricial alopecia is the destructive inflammation of the hair follicle which is referred 
to different etiologies and it is generally autoimmune processes.
It is essential to examine the whole scalp and skin biopsies for finding the main reason for cic‐
atricial alopecia are necessary. There are three main groups for primary cicatricial alopecia: 
lymphocytic, neutrophilic and mixed. It is classified according to the types of inflammatory 
cells examined histologically where hair follicles are affected. It could be so difficult to differ‐
entiate the primary cicatricial alopecia types because of the various forms of this disease and 
it ends with complete hair loss. The most visible symptom of this disease is the active inflam‐
mation. In this condition, the most substantial aim for treatment is to stop or slow down the 
development of this disease. For the patients with lymphocytic primary cicatricial alopecia, 
topical and intralesional corticosteroids and antimalarials can be applied and in persistent 
conditions, systemic immunosuppressive agents can be tried. The applications of antibiot‐
ics and retinoids are the most essential medications to treat neutrophilic cicatricial alopecia.
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Telogen effluvium is characterized by diffuse loss of telogen hair. Telogen effluvium is 
a non‐inflammatory disease. The main reason for this disease is still unknown, but it is 
most frequent reason for hair loss. In a normal scalp, 90–95% of the hair follicles are in the 
anagen phase, and 5–10% are in the telogen phase. It is normal to lose 100 hairs in a day. 
In telogen effluvium disease, the ratio or the number of hair follicles increases. According 
to various follicular cycles, five types of functional telogen effluvium have been found. The 
types include the immediate anagen release, delayed anagen release, immediate telogen 
release, delayed telogen release and short anagen phase. The pathological causes of this 
disease are exogenous factors,  inflammatory diseases, some drugs and connective tissue 
disorders such as systemic lupus erythematous, stress, organ dysfunctions, endocrine dis‐
orders, syphilis and nutritional causes.
This disease can be seen as acute and chronic and it is classified according to its duration. If 
the duration of disease is shorter than 6 months, it is known as acute telogen effluvium; if the 
hair loss is longer than 6 months, it is accepted as chronic telogen effluvium. The hair loss 
can be apparent 2 or 3 months later in acute telogen effluvium disease. The aetiologic factors 
or events of telogen effluvium may not be detected in 33% of the patients. Some tests can be 
applied to patients such as the hair‐pull test and the result of this test is positive. In addition 
to that, inflammation is not found in telogen effluvium. In the trichogram test, the telogen hair 
ratio reaches above 25% in telogen effluvium. A fine evaluation is to be done to understand 
the real cause and the most substantial factors: to treat telogen effluvium is to find the natural 
process of telogen effluvium. If the triggering factor of this disease can be found and stopped, 
hair loss will generally decrease within 3–6 months [15, 16].
Trichotillomania was observed several years ago, but there have been little data about 
treatment and its etiology. It can be described as an impulse control disorder and it is 
identified by chronic hair pulling. Trichotillomania (hair‐pulling disorder) is a type of trac‐
tional alopecia. In every types of hair loss, this disease has also affected the quality of life 
and relations in a negative way. When we look at the history of the disease, it was identified 
in DSM‐III‐R (Diagnostic and Statistical Manual of Mental Disorders, Third Edition) in 1987; in 
that study, continual hair pulling was described as a psychiatric disorder. Hair pulling is 
not known as rational behaviour in medical condition (e.g., dermatological problems) and 
it is a psychiatric disorder. The repeated attitude cannot be stopped and finally it causes 
hair loss. The reason for this disease can also be subjective nuisance and deterioration in 
social life. The patients not only pull the hair from the scalp but they also pull the hair 
from other body areas such as the eyebrows, beard, eyelashes, arms, groin and moustache.
The symptoms of trichotillomania resemble the obsessive‐compulsive spectrum, so this dis‐
ease is mainly included among psychiatric diseases [17]. Trichotillomania usually begins in 
early ages and become chronic with gradual events. It can also be seen in adolescence at the 
beginning of 12 years. The adults can also face this disease at old ages. Trichotillomania can be 
confused with AA in older patients in the first phase of the disease because it appeared mostly 
in females [18, 19]. When we observe more than a third of paediatric patients with trichotil‐
lomania, there have been many psychiatric disorders such as attention deficit‐hyperactivity 
disorder, anxiety disorder, obsessive‐compulsive disorder and depression. But unfortunately, 
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the studies show that 40% of the trichotillomania patients could not be diagnosed and 58% 
patients never received correct medications [20].
Trichophagy is a kind of disease which is described as putting the hair into the mouth. 
Trichophagy can cause serious diseases such as vomiting, ileus and weight loss. Hair swal‐
lowing has been shown in 5–18% of these patients [19, 21].
2. Diagnosis
It has been understood that there have been many reasons for hair loss. Dermatologists always 
apply different methods for finding the main evidence of the disease. The dermatologist also 
will carefully look at patient's scalp and hair. For instance, they have to pull their patients’ 
hair to get the true results, and it is named as ‘pull test’. Pulling hair test can be helpful to 
describe the process of hair loss. And dermatologists should sometimes observe the whole 
body to understand the ratio of hair loss. To make sure about the evidence, they also use 
blood tests. By using blood tests, they can find other reasons for hair loss such as iron defi‐
ciency, anaemia, thyroid disease or vitamin deficiencies. The dermatologists can also apply 
punch biopsy to detect histopathological reasons. All of the applications should be done to 
find out some clues in your scalp [22].
Although medical treatment is a useful method for patients and physicians, the results of 
treatment could be unsuccessful. Instead of other techniques, hair transplantation should be 
used for androgenetic alopecia. Hair transplantation method is essential not only for androge‐
netic alopecia but also good for other kinds of hair loss. The other kinds of problems include 
cicatricial alopecias, congenital alopecias, post‐burn sequelae and alopecia areata [23]. Lately, 
hair transplantation has been common for treating hair loss. ‘Follicular unit transplantation’ 
and ‘Follicular unit extraction’ are the main types of this method. In follicular unit transplan‐
tation, occipital region is the main area for taking skin patches; they can be separated manu‐
ally to grafts and put to the recipient area. ‘Follicular unit extraction’ is the other method in 
order to treat hair loss. In this method, 1‐mm diameter micrografts are taken from the donor 
area and they are transferred to predrilled holes. This technique is less painful and more 
comfortable for patients because it does not cause a linear scar. The essential disadvantage of 
this treatment is that patients should spend much more time for extracting grafts. Due to the 
‘punched–out’ sites, donor transferring into the area can be limited [24, 25].
3. Psychosocial effects
Alopecia occurs not only for physical reasons but also because of psychological problems. 
They have a major role in this serious condition. It has a significant psychological impact on 
the quality of life.
The incidence of alopecia always increases because of the psychological problems. Patients 
with alopecia are exposed to mental disorders such as post‐traumatic stress disorder, social 
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phobia, depression, anxiety and suicidal thoughts. Psychological/psychiatric disorders have 
been detected at rates up to 60% in dermatology patients treated as inpatients [26].
Mental disorders are observed to be a higher risk among women with scarring alopecia. Hair 
loss can be an important reason for psychological/psychiatric problems such as embarrass‐
ment, depression, anxiety about their appearance, low self‐esteem, anger, less social and 
sexual activity and even suicidal thoughts. Because of the connection between alopecia and 
mental disorders, dermatologists and psychologists/psychiatrists have to find the main rea‐
sons for the hair loss together [27, 28].
The aim of this chapter is to review the latest developments in the understanding of hair loss 
and its treatment. The contents cover the molecular and cell biological aspects of hair follicles 
through to the pathogenesis of alopecia, its treatment with topical and systemic agents, and new 
treatment options such as hair transplantation, mesotherapy and platelet‐rich plasmas (PRPs).
Author details
Zekayi Kutlubay* and Server Serdaroglu
*Address all correspondence to: zekayikutlubay@hotmail.com
 Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
References
[1] Buffoli B, Rinaldi F, Labanca M et al. The human hair: from anatomy to physiology. Int 
J Dermatol 2014;53:331–341.
[2] Krause K, Foitzik K. Biology of hair follicle: the basics. Semin Cutan Med Surg 
2006;25:2–10.
[3] Wolfram LJ. Human hair: A unique physicochemical composite. J Am Acad Dermatol 
2003;48:S106–114.
[4] Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001;81:449–494.
[5] Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K, Kawamura T et al. Combination ther‐
apy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol 
Res 2009;301:373–380.
[6] Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alo‐
pecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest 
Dermatol 2014;134:1141–1142. DOI: 10.1038/jid.2013.464.
[7] Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki‐Schulze A, Koumantaki E, Karpouzis 
A et al. Oral administration of cyclosporin A in patients with severe alopecia areata. Int 
J Tissue React 2005;27:107–110.
Hair and Scalp Disorders8
[8] Smith JR, Akin RS, Wells MJ. Alopecia areata treated with efalizumab: a case with sig‐
nificant hair re‐growth after long‐term therapy. J Drugs Dermatol 2009;8:758–760.
[9] Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A et al. Etanercept does not 
effectively treat moderate to severe alopecia areata: an open‐label study. J Am Acad 
Dermatol 2005;52:1082–1084.
[10] D'Ovidio R. Alopecia areata: news of diagnosis, pathogenesis, and treatment. Ital J 
Dermatol Venereol 2014;149:25–45.
[11] Holzer AM, Kaplan LL, Lewis WR. Haptens as drugs: contact allergens are powerful 
topical immunomodulators. J Drugs Dermatol 2006;5;410–416.
[12] Colon EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK. Lifetime prevalence of 
psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991;32:245–
251. DOI: 10.1016/0010‐440X(91)90045‐E.
[13] Elston CA, Elston DM. Hair Disorders: Finding the Root of the Problem. May 24, 
2016; Accessed August 20, 2016. Available at http://reference.medscape.com/features/
slideshow/hair‐disorders#page=2.
[14] Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for 
therapy. Expert Rev Mol Med 2002;4:1–11. DOI: 10.1017/S1462399402005112.
[15] Shapiro J. Clinical practice. Hair loss in women. N Engl J Med 2007; 18;357(16):1620–
1630. DOI: 10.1056/NEJMcp072110.
[16] Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002;27(5):389–395. PMID: 
12190639.
[17] Van Ameringen M, Patterson B, Simpson W. DSM‐5 obsessive‐compulsive and related 
disorders: clinical implications of new criteria. Depress Anxiety. 2014;31:487–493. DOI: 
10.1002/da.22259.
[18] Papadopoulos AJ, Janniger CK, Chodynicki MP, Schwartz RA. Trichotillomania. Int J 
Dermatol 2003;42:330–334. DOI: 10.1046/j.1365‐4362.2003.01147.x.
[19] Fettahoğlu EÇ. Hair loss related to primary psychiatric disorders. TURKDERM 
2014;48:52–55. DOI: 10.4274/turkderm.48.s12.
[20] Cohen LJ, Stein DJ, Simeon D, Spadaccini E, Rosen J, Aronowitz B, et al. Clinical profile, 
comorbidity, and treatment history in 123 hair pullers: a survey study. J Clin Psychiatry 
1995;56:319–326. PMID: 7615485.
[21] Tolin DF, Franklin ME, Diefenbach GJ, Anderson E, Meunier SA. Pediatric trichotillo‐
mania: descriptive psychopathology and an open trial of cognitive behavioral therapy. 
Cogn Behav Ther 2007;36:129–144. DOI: 10.1080/16506070701223230.
[22] Spano F, Donovan JC. Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis. 
Can Fam Phys 2015; 61:751–755.
Introductory Chapter: Hair Loss
http://dx.doi.org/10.5772/66984
9
[23] Ors S, Ozkose S, Ors S. Follicular unit extraction hair transplantation with micromotor: 
eight years experience. Aesthetic Plast Surg 2015;39(4):589–596.
[24] Kutlubay Z, Kucuktas M, Engin B. Hair transplantation in the cicatricial alopecias. Hair 
Ther Transplant 2013; 3:109. doi:10.4172/2167‐0951.1000109.
[25] Harris JA. Follicular unit extraction (FUE). In: Avram MR, Rogers NE (eds), Hair 
Transplantation, Cambridge Medicine, Cambridge, 2010; 23–34.
[26] Gupta MA, Gupta AK. Psychiatric and psychological co‐morbidity in patients with der‐
matologic disorders: epidemiology and management. Am J Clin Dermatol 2003;4:833–
842. PMID: 14640776.
[27] Yazıcı E, Erol A. Psychiatric approach to alopecia. Turkiye Klinikleri J Cosm Dermatol‐
Special Topics 2015;8:73–78.
[28] Aghaei S, Saki N, Daneshmand E, Kardeh B. Prevalence of psychological disorders 
in patients with alopecia areata in comparison with normal subjects. ISRN Dermatol 
2014;2014:304370. DOI: http://dx.doi.org/10.1155/2014/304370.
Hair and Scalp Disorders10
